John Betteridge, MD
Gastroenterology · Lancaster, PANPI 1447354410
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $240,869 of the $309,604 with a category attached, or 77.8%. 34 manufacturers reported payments, led by AbbVie at 49.9% of the total. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 553 payments — averaging $559.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$155K
- Pfizer$77K
- Johnson & Johnson$70K
- Janssen Scientific Affairs, LLC$4K
- Takeda Pharmaceuticals U.S.A., Inc.$548
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$548
- plus $2K from 28 others
What the payments were for
- Consulting fees$19,5886%
- Speaking & faculty fees$240,86978%
- Travel & lodging$36,98412%
- Food & beverage$12,1564%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 226 | $154,623 |
| Pfizer | 85 | $77,267 |
| Johnson & Johnson | 70 | $70,482 |
| Janssen Scientific Affairs, LLC | 4 | $4,050 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $548 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $548 |
| Bristol Myers Squibb | 14 | $275 |
| Sanofi | 8 | $201 |
| Celltrion USA Inc. | 8 | $165 |
| Lilly USA, LLC | 7 | $146 |
| Ardelyx, Inc. | 7 | $145 |
| Fresenius Kabi USA, LLC | 7 | $132 |
| Regeneron Healthcare Solutions, Inc. | 4 | $111 |
| Merck | 6 | $109 |
| Novo Nordisk | 5 | $103 |
| Ferring Pharmaceuticals Inc. | 4 | $82 |
| Ironwood Pharmaceuticals, Inc | 6 | $79 |
| Intercept Pharmaceuticals, Inc. | 5 | $75 |
| Boehringer Ingelheim | 2 | $58 |
| Amgen | 2 | $50 |
| Boston Scientific | 3 | $48 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Gilead | 3 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| QOL Medical, LLC | 1 | $24 |
| Capsovision, Inc. | 1 | $22 |
| UCB, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Sandoz | 1 | $16 |
| Shionogi Inc | 1 | $16 |
| Romark Laboratories, LC | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$309,604 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 71 | $2,171,478 |
| Humira(Cf) PenAdalimumab | 59 | $585,429 |
| EntyvioVedolizumab | 22 | $191,318 |
| InflectraInfliximab-Dyyb | 25 | $179,781 |
| Humira(Cf)Adalimumab | 11 | $156,867 |
| RinvoqUpadacitinib | 12 | $112,270 |
| XeljanzTofacitinib Citrate | 12 | $68,293 |
| AvsolaInfliximab-Axxq | 11 | $39,756 |
| XifaxanRifaximin | 11 | $33,684 |
| Mesalamine | 20 | $11,649 |
| Mesalamine ErMesalamine | 35 | $8,440 |
| Mesalamine DrMesalamine | 13 | $4,110 |
| Lansoprazole | 25 | $3,187 |
| Colestipol Hcl | 11 | $2,847 |
| Azathioprine | 24 | $2,563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $70,482 | $2,171,47871 claims |
| AbbVieHumira(Cf), Rinvoq | $154,623 | $269,13723 claims |
| PfizerInflectra, Xeljanz | $77,267 | $248,07437 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $548 | $191,31822 claims |
| AmgenAvsola | $50 | $39,75611 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $548 | $33,68411 claims |
| SandozLansoprazole | $16 | $3,18725 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $132 | $7519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Lancaster
- Paul AllegrettiLancaster$73K
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
- Kofi ClarkeHershey$426K
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Elie AounPittsburgh$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.